Renaissance Capital logo

Immix Biopharma Priced, Nasdaq: IMMX

Phase 1b/2a biotech developing tissue-specific therapies for solid tumors.

Industry: Health Care

Latest Trade: $3.07 0.00 (0.0%)

First Day Return: -26.6%

Return from IPO: -38.6%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”) in oncology and inflammation. Our lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously), and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging our TME Normalization Technology, delivered deep into the tumor micro-environment (“TME”). Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. As of the date of this prospectus, we have not generated any revenues. Since inception, we have devoted substantially all of our resources to developing product and technology rights, conducting research and development, organizing and staffing our Company, business planning and raising capital.
more less
IPO Data
IPO File Date 09/17/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 4.2
Deal Size ($mm) $21
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 12/15/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 4.2
Deal Size ($mm) $21
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
ThinkEquity
Company Data
Headquarters Los Angeles, CA, United States
Founded 2012
Employees 9
Website www.immixbio.com

Immix Biopharma (IMMX) Performance